No abstract available.
Neuroleptic Malignant Syndrome*

We report a patient developed neuroleptic malignant syndrome (NMS) with myoglobulinemic acute renal failure and lithium intoxication due to lithium-olanzapine combination, who was successfully treated by hemodiafiltration. A 34-year-old woman with a 14-year history of bipolar disorder had been treated with lithium-olanzapine during last four days. She was admitted to our hospital for muscular rigidity, hyperthermia and altered consciousness. On admission, rhabdomyolsis was demonstratd by biochemical methods and serum level of lithium was 3.78 mEq/L which was far above toxic level. After the diagnosis of NMS with acute renal failure and lithium intoxication, olanzapine and lithium were discontinued and conservative measures and continuous venovenous hemodiafiltration were instituted. She recovered without any neurologic sequelae.
Female ; Humans ; Neuroleptic Malignant Syndrome

No abstract available.
Levodopa* ; Neuroleptic Malignant Syndrome* ; Parkinson Disease*

Neuroleptic malignant syndrome (NMS) is a fatal complication most often caused by an adverse reaction to neuroleptic or antipsychotic drugs, and is mostly brought out in the initial stage of medication. Late onset NMS after long term intake of neuroleptics is uncommon, and the neurochemical mechanism is undiscovered. We report a patient of late onset NMS after a long term intake of haloperidol who was successfully treated with dantrolene and bromocriptine.
Antipsychotic Agents ; Bromocriptine ; Dantrolene ; Haloperidol ; Humans ; Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

Aged ; Humans ; Male ; Neuroleptic Malignant Syndrome ; etiology ; physiopathology ; Parkinson Disease ; drug therapy ; Substance Withdrawal Syndrome

Several studies have reported on catatonia caused by the use of antipsychotic drugs and on the association between catatonia and neuroleptic malignant syndrome (NMS), but none has reported such a case in Korea. Here, we report the case of a 20-year-old woman whose catatonia and NMS appeared associated with the administration of an atypical antipsychotic drug. We discuss the association between NMS and catatonia due to neuroleptic use.
Antipsychotic Agents ; Catatonia ; Female ; Humans ; Korea ; Neuroleptic Malignant Syndrome ; Young Adult

We report a case of atypical neuroleptic malignant syndrome (NMS) induced by olanzapine. It was expected that this atypical agent would not cause dystonia or NMS due to its unique mechanism of action with attenuated anti-dopamin-ergic activity and potentiated antiserotonergic activity, as well as other anti-cholinergic activity. We report the case of a 74-year-old male patient with Alzheimer's disease in whom signs and symptoms consistent with NMS developed following 2 weeks of olanzapine therapy. The patient presented with fever, changes in mental status, tremor, and rigidity. His laboratory findings were significant for increased serum creatine phosphokinase. The NMS subsided after treatment and the restart of olanzapine therapy was performed successfully. There have been few reported cases of olanzapine-induced NMS. Health care providers should be aware of the risk of olanzapine-induced NMS.
Aged ; Alzheimer Disease ; Creatine Kinase ; Dystonia ; Fever ; Health Personnel ; Humans ; Male ; Neuroleptic Malignant Syndrome ; Tremor

Risperidone is a relatively new antipsychotic agent. It is often referred to as 'atypical', because it has a mechanism of action that blocks post synaptic dopamine-2 and serotonin-2 receptors, it is associated with fewer extrapyramidal side effects, it is not yet associated with tardive dyskinesia, and it may have some efficacy on negative symptoms of schizophrenia. In despite of its 'atypical' nature, there are already more than 15 reports of risperidone-induced neuroleptic malignant syndrome. Only one case of risperidone-induced NMS was reported recently in Korea. We report one case of delayed risperidoneinduced neuroleptic malignant syndrome in young male patient and review the related articles.
Humans ; Korea ; Male ; Movement Disorders ; Neuroleptic Malignant Syndrome* ; Receptors, Serotonin, 5-HT2 ; Risperidone ; Schizophrenia